DeepMed Research

Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

Phase 4

Recruiting

Conditions: Muscular Atrophy, Spinal

Interventions: Drug: risdiplam

First Posted Date: 2023-05-17

Last Posted Date: 2025-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 28

Registration Number: NCT05861999

Locations: 🇺🇸
Children'S Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Valley Children's Hospital, Madera, California, United States

and more 15 locations

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Phase 3

Recruiting

Conditions: Cancer

Interventions: Drug: Ipatasertib
Drug: Tiragolumab
Drug: Atezolizumab
Drug: Bevacizumab
Drug: Tiragolumab and Atezolizumab
Drug: Entrectinib
Drug: Inavolisib

First Posted Date: 2023-05-17

Last Posted Date: 2025-05-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT05862285

Locations: 🇨🇷
Clinica CIMCA, San José, Costa Rica
🇧🇪
GHdC Site Les Viviers, Charleroi, Belgium
🇧🇪
AZ Groeninge, Kortrijk, Belgium

and more 24 locations

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Tobemstomig
Drug: Pembrolizumab
Drug: Nab-Paclitaxel

First Posted Date: 2023-05-10

Last Posted Date: 2025-05-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 83

Registration Number: NCT05852691

Locations: 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
🇺🇸
Cancer Blood and Specialty Clinic, Los Alamitos, California, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 35 locations

A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer

Phase 4

Completed

Conditions: Metastatic Gastrointestinal Cancer
Metastatic Lung Cancer

Interventions: Diagnostic Test: FoundationOne® Liquid CDx Assay
Diagnostic Test: Standard of Care Diagnostic Pathway

First Posted Date: 2023-05-06

Last Posted Date: 2024-12-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 466

Registration Number: NCT05846594

Locations: 🇫🇷
Centre Oscar Lambret; Chir Cancerologie General, Lille, France
🇫🇷
Hopital Marie Lannelongue, Le Plessis Robinson, France
🇫🇷
Institut Sainte Catherine;Recherche Clinique, Avignon, France

and more 16 locations

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus

Phase 1

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: RO7507062
Drug: Tocilizumab

First Posted Date: 2023-04-28

Last Posted Date: 2025-05-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 70

Registration Number: NCT05835986

Locations: 🇨🇴
Oncomedica S.A., Monteria, Colombia
🇨🇴
Clinica De La Costa, Barranquilla, Colombia
🇨🇴
Hospital Pablo Tobon Uribe, Medellin, Colombia

and more 20 locations

A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy

Phase 2

Recruiting

Conditions: Muscular Atrophy, Spinal

Interventions: Drug: Risdiplam

First Posted Date: 2023-04-11

Last Posted Date: 2025-05-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 10

Registration Number: NCT05808764

Locations: 🇺🇸
University Of Michigan, Ann Arbor, Michigan, United States
🇵🇱
Instytut Pomnik - Centrum Zdrowia Dziecka, Warszawa, Poland
🇺🇸
Ann and Robert H. Lurie Children Hospital of Chicago, Chicago, Illinois, United States

and more 10 locations

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Renal Cell Carcinoma

Interventions: Drug: Tobemstomig
Drug: Pembrolizumab
Drug: Axitinib
Drug: Tiragolumab

First Posted Date: 2023-04-10

Last Posted Date: 2025-05-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 199

Registration Number: NCT05805501

Locations: 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇫🇷
CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre, Bordeaux, France
🇫🇷
Centre Francois Baclesse, Caen, France

and more 44 locations

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Phase 3

Recruiting

Conditions: Primary IgA Nephropathy

Interventions: Drug: sefaxersen (RO7434656)
Drug: Placebo

First Posted Date: 2023-04-04

Last Posted Date: 2025-05-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 428

Registration Number: NCT05797610

Locations: 🇫🇷
Hopital Bichat - Claude Bernard AP-HP, Paris, France
🇫🇷
Hôpital de Rangueil, Toulouse, France
🇪🇸
Hospital Universitario La Paz - PPDS, Madrid, Spain

and more 174 locations

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Divarasib
Drug: Pembrolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed

First Posted Date: 2023-03-29

Last Posted Date: 2025-05-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 240

Registration Number: NCT05789082

Locations: 🇨🇦
Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
City of Hope - Seacliff, Huntington Beach, California, United States

and more 58 locations

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Tobemstomig
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2023-03-20

Last Posted Date: 2025-04-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 180

Registration Number: NCT05775289

Locations: 🇩🇪
Krankenhaus Martha-Maria Halle-Doelau, Halle (Saale), Germany
🇮🇹
Azienda Ospedaliera San Giuseppe Moscati, Avellino, Campania, Italy
🇮🇹
AZ.Osp S. Orsola ? Malpighi-Reparto di Oncologia Medica, Bologna, Emilia-Romagna, Italy

and more 48 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy